Transplantation and cellular therapy
Guidelines for the Prevention and Management of Graft-versus-Host Disease after Cord Blood Transplantation
Abstract
The incidence of graft-versus-host disease (GVHD) after cord blood (CB) transplantation (CBT) is lower than expected given the marked degree of human leukocyte antigen (HLA)-mismatch of CB grafts. While the exact mechanism that underlies this biology remains unclear, it is hypothesized to be due to the low number of mostly immature T-cells infused as part of the graft1,2, and increased tolerance of CB-derived lymphocytes induced by the state of pregnancy. Nevertheless, acute GVHD (aGVHD) is a significant complication of CBT. In contrast, the incidence of chronic GVHD (cGVHD) following CBT is lower than what is observed following matched related or unrelated donor HSC transplantation (HSCT)3-6. This review outlines the guidelines for the prevention and management of acute and chronic GVHD following CBT.
Source and rights
Published by Transplantation and cellular therapy, 2021. The guideline itself is at the source linked here.
Prognia summarises this guideline for reference and education. It is not medical advice. Always check the official guideline and current local protocols before acting on it.
At a glance
- Published
- 2021
- Applies to
- 🇪🇺 Europe
- Scope
- Regional
- Journal
- Transplantation and cellular therapy
- PubMed
- 34210500
More in surgery
- American Society for Metabolic and Bariatric Surgery review of endobariatric proceduresAmerican Society for Metabolic and Bariatric Surgery · 2026
- Non-pneumatic compression and its clinical utility in management of lymphedema. A position statement endorsed by the American Venous Forum and the American Venous and Lymphatic SocietyAmerican Venous Forum and American Venous and Lymphatic Society · 2026
